Syntis Bio Taps Matthew Dallas as CFO

Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that leverage the small intestine, has appointed Matthew Dallas as Chief Financial Officer (CFO).

“With Matt’s appointment, we continue to assemble a leadership team with the expertise and experience needed to scale Syntis Bio’s financial and business infrastructure as we rapidly advance multiple pipeline programs, including SYNT-101, the Company’s lead investigational program for the treatment of obesity,” said Rahul Dhanda, CEO of Syntis Bio. “Matt has navigated the full arc of building a biopharmaceutical company – from public and private financing strategies to scaling operations to forging partnerships. He will be a tremendous asset as we build our financial foundation and look towards our next phase of growth and long-term success.”

Experience

Dallas brings more than 25 years of financial expertise and management experience in the life sciences industry.

He most recently served as Chief Financial Officer of Pulmocide, where he oversaw all aspects of the company’s capital strategy, finance, and investor relations functions. Prior to Pulmocide, Dallas served as Chief Financial Officer of Zealand Pharma, a Danish biotechnology research company that designs and develops peptide-based medicines mainly focusing on metabolic diseases. Before Zealand, he held CFO roles with AVEO Oncology and CoLucid Pharmaceuticals. At CoLucid, he helped lead the company’s initial public offering and subsequent acquisition by Eli Lilly and Company.

Dallas holds a B.S. in finance from the University of Tennessee, Knoxville and serves on the University’s Finance Department Advisory Council.

“I’m excited to join Syntis and for the opportunity to be part of a company developing the next generation of solutions for metabolic health,” said Dallas. “I look forward to working closely with Rahul and the leadership team to scale our business and support it through financial strategies that translate into significant value creation while delivering new therapies to patients who need them.”